Therapeutic Approaches for Treating and Preventing Relapses in NMOSD
We review current (and future) therapies for neuromyelitis optica spectrum disorder and discuss how the treatment landscape Is changing.
NMOSD Insights
Antibodies and Medical Imaging Figure Prominently in Diagnosis of NMOSD
With the updated definition of neuromyelitis optica spectrum disorder in 2015, studies have estimated a rise of around 1.5 fold in disease prevalence.
Comparing First-Line Immunosuppressants Used in NMOSD
We compare the most common types of first-line immunosuppressants currently used to treat neuromyelitis optica spectrum disorder (NMOSD).
Exploring the Possible Association Between COVID-19 Vaccines and NMOSD
Researchers are investigating anecdotal reports of NMOSD relapse associated with COVID-19 vaccines and examining the science behind them.
Assessing the Risk Factors for Relapse in Patients With NMOSD
In the management of any disease in which relapses are known to occur, it is important to identify the risk factors for their occurrence, as well as any other factors that might influence their severity. In this article, we will be assessing the risk factors for relapse in patients with neuromyelitis optica spectrum disorder (NMOSD)…
The Mechanisms and Efficacy of New Immunosuppressive Therapies For NMOSD
We explore the efficacy and mechanisms of 3 immunosuppressive therapies that have been approved for use in neuromyelitis optica spectrum disorder (NMOSD).
Contrasting Patterns of Gray Matter Damage Across Subtypes of MS
Investigators strove to quantify imaging patterns of central nervous system damage in MOGAD during the remission stage, and to compare it with NMOSD-AQP4 and MS.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in News Briefs
Loading... 
Loading...